ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Purchases 60,000 Shares

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster acquired 60,000 shares of ProMIS Neurosciences stock in a transaction that occurred on Friday, September 20th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $75,000.00. Following the transaction, the director now directly owns 68,333 shares in the company, valued at $85,416.25. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

ProMIS Neurosciences Trading Down 1.5 %

Shares of PMN stock opened at $1.29 on Friday. The firm has a market capitalization of $24.46 million, a price-to-earnings ratio of -1.74 and a beta of 0.62. The business’s 50-day moving average price is $1.38 and its 200-day moving average price is $1.71. ProMIS Neurosciences, Inc. has a 12 month low of $0.95 and a 12 month high of $3.10.

ProMIS Neurosciences (NASDAQ:PMN) last posted its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. On average, sell-side analysts predict that ProMIS Neurosciences, Inc. will post -0.24 earnings per share for the current fiscal year.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.